Summary
This is a 26-week study to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Official Title
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
Keywords
Generalized Myasthenia Gravis, IMVT-1402, Acetylcholine receptor, Muscle-specific kinase, Autoantibody, Lipoprotein receptor-related protein 4, Autoimmune disease, Neonatal fragment crystallizable receptor (FcRn), Myasthenia Gravis, Autoimmune Diseases, Counterfeit Drugs